文献速递炎症性肠病

法国全国队列:IBD孕妇硫唑嘌呤与抗TNF治疗的妊娠结局比较

Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.
PubMed 文献 · Aliment Pharmacol Ther · 2021-06-23

基于法国2010-2018年全国健康数据库27 729例IBD孕妇,比较硫唑嘌呤单药、抗TNF单药及联合治疗与未暴露妊娠的结局。硫唑嘌呤单药与死产、早产和大于胎龄儿风险升高相关,抗TNF单药未见这些差异。

要点

  • 硫唑嘌呤单药暴露者死产风险高于未暴露者(1.0% vs 0.5%,aOR 2.04)。
  • 硫唑嘌呤单药暴露者早产风险升高(12.3% vs 7.1%,aOR 1.76)。
  • 抗TNF单药暴露者死产、早产和大于胎龄儿风险与未暴露者无差异。

核心结论

  • 硫唑嘌呤暴露妊娠较抗TNF暴露或未暴露妊娠更常出现死产、早产和大于胎龄儿。
  • 抗TNF单药暴露与这些不良妊娠结局无关联。

研究设计与样本

  • 纳入2010-2018年间以活产或死产结束的IBD孕妇妊娠共27 729例。
  • 暴露分组:硫唑嘌呤单药3554例、抗TNF单药3525例、联合治疗839例、未暴露19 811例。
  • 采用倾向评分加权边际logistic回归模型比较妊娠结局。

主要发现

  • 硫唑嘌呤单药 vs 未暴露:死产1.0% vs 0.5%(aOR 2.04;95%CI: 1.18-3.55)。
  • 硫唑嘌呤单药 vs 未暴露:早产12.3% vs 7.1%(aOR 1.76;95%CI: 1.55-2.00)。
  • 硫唑嘌呤单药 vs 未暴露:大于胎龄儿10.6% vs 8.4%(aOR 1.32;95%CI: 1.13-1.53)。
  • 硫唑嘌呤单药 vs 未暴露:小于胎龄儿9.6% vs 11.1%(aOR 0.79;95%CI: 0.67-0.92)。
  • 联合治疗 vs 未暴露:早产aOR 1.55(95%CI: 1.15-2.11)、大于胎龄儿aOR 1.61(95%CI: 1.13-2.29),死产无差异。

临床怎么用

  • IBD孕妇使用硫唑嘌呤单药时需关注死产、早产及大于胎龄儿风险,加强孕期监测。
  • 抗TNF单药在妊娠期未显示与死产、早产或大于胎龄儿风险增加相关。
  • 联合治疗需关注早产和大于胎龄儿风险。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data about thiopurines or anti-TNF use during pregnancy in women with inflammatory bowel diseases (IBD) are reassuring. However, many studies are based upon small sample sizes. AIMS: To assess IBD medication safety during pregnancy. METHODS: Using the French national health database, which covers more than 99% of the French population, around 65 000 000 people, we identified pregnancies ending with a birth in IBD patients in France between 2010 and 2018. Pregnancy outcomes (vital status at birth, birth term, and weight for gestational age) were compared according to treatment exposure during pregnancy using propensity score-weighted marginal logistic regression models. RESULTS: 27 729 pregnancies were included: 3554 were exposed to thiopurines monotherapy, 3525 to anti-TNF monotherapy, 839 to combination therapy, and 19 811 unexposed. Pregnancies exposed to thiopurines monotherapy compared to unexposed pregnancies more frequently resulted in stillbirths (1.0% vs 0.5%, aOR 2.04; 95%CI: 1.18-3.55), preterm birth (12.3% vs 7.1%, aOR 1.76; 95%CI: 1.55-2.00), large for gestational age (10.6% vs 8.4%, aOR 1.32; 95%CI: 1.13-1.53) and less frequently in small for gestational age (9.6% vs 11.1%, aOR 0.79; 95%CI: 0.67-0.92). By contrast, pregnancies exposed to anti-TNF monotherapy were not different from unexposed pregnancies as regards to these outcomes. Compared to unexposed pregnancies, those exposed to combination therapy more frequently resulted in preterm births (aOR 1.55; 95%CI: 1.15-2.11) and larger for gestational age (aOR 1.61; 95%CI: 1.13-2.29) but did not differ as regards to stillbirths. CONCLUSIONS: Pregnancies exposed to thiopurines more frequently resulted in stillbirths, preterm births and large for gestational age compared to pregnancies exposed to anti-TNF or unexposed pregnancies. By contrast, pregnancies exposed to anti-TNF monotherapy were not associated with these outcomes.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Meyer A, Drouin J, Weill A, et al. Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018. Aliment Pharmacol Ther. 2021. PMID: 34162011. doi:10.1111/apt.16448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。